FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085753048> ?p ?o ?g. }

• W2085753048 endingPage "3071" @default.
• W2085753048 startingPage "3061" @default.
• W2085753048 abstract "Abstract Objective Studies have suggested that rheumatoid arthritis (RA) and osteoarthritis (OA) share common characteristics. The highly selective A 3 adenosine receptor agonist CF101 was recently defined as a potent antiinflammatory agent for the treatment of RA. The purpose of this study was to examine the effects of CF101 on the clinical and pathologic manifestations of OA in an experimental animal model. Methods OA was induced in rats by monosodium iodoacetate, and upon disease onset, oral treatment with CF101 (100 μg/kg given twice daily) was initiated. The A 3 adenosine receptor antagonist MRS1220 (100 μg/kg given twice daily) was administered orally, 30 minutes before CF101 treatment. The OA clinical score was monitored by knee diameter measurements and by radiographic analyses. Histologic analyses were performed following staining with hematoxylin and eosin, Safranin O–fast green, or toluidine blue, and histologic changes were scored according to a modified Mankin system. Signaling proteins were assayed by Western blotting; apoptosis was detected via immunohistochemistry and TUNEL analyses. Results CF101 induced a marked decrease in knee diameter and improved the changes noted on radiographs. Administration of MRS1220 counteracted the effects of CF101. CF101 prevented cartilage damage, osteoclast/osteophyte formation, and bone destruction. In addition, CF101 markedly reduced pannus formation and lymphocyte infiltration. Mechanistically, CF101 induced deregulation of the NF‐κB signaling pathway, resulting in down‐regulation of tumor necrosis factor α. Consequently, CF101 induced apoptosis of inflammatory cells that had infiltrated the knee joints; however, it prevented apoptosis of chondrocytes. Conclusion CF101 deregulated the NF‐κB signaling pathway involved in the pathogenesis of OA. CF101 induced apoptosis of inflammatory cells and acted as a cartilage protective agent, which suggests that it would be a suitable candidate drug for the treatment of OA." @default.
• W2085753048 created "2016-06-24" @default.
• W2085753048 creator A5003547159 @default.
• W2085753048 creator A5004222660 @default.
• W2085753048 creator A5023006840 @default.
• W2085753048 creator A5035698889 @default.
• W2085753048 creator A5035905868 @default.
• W2085753048 creator A5046483439 @default.
• W2085753048 creator A5049958479 @default.
• W2085753048 creator A5057189629 @default.
• W2085753048 creator A5061107236 @default.
• W2085753048 creator A5067900184 @default.
• W2085753048 creator A5073066369 @default.
• W2085753048 creator A5077471575 @default.
• W2085753048 creator A5081286017 @default.
• W2085753048 date "2009-09-29" @default.
• W2085753048 modified "2023-10-11" @default.
• W2085753048 title "Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment" @default.
• W2085753048 cites W1480259844 @default.
• W2085753048 cites W1774678646 @default.
• W2085753048 cites W1826976540 @default.
• W2085753048 cites W1988145586 @default.
• W2085753048 cites W1990065831 @default.
• W2085753048 cites W1996687502 @default.
• W2085753048 cites W2009524387 @default.
• W2085753048 cites W2010802338 @default.
• W2085753048 cites W2011418006 @default.
• W2085753048 cites W2018777822 @default.
• W2085753048 cites W2026575610 @default.
• W2085753048 cites W2032850298 @default.
• W2085753048 cites W2038083756 @default.
• W2085753048 cites W2044833301 @default.
• W2085753048 cites W2052396430 @default.
• W2085753048 cites W2064150573 @default.
• W2085753048 cites W2071919658 @default.
• W2085753048 cites W2073512971 @default.
• W2085753048 cites W2074924992 @default.
• W2085753048 cites W2082273415 @default.
• W2085753048 cites W2088829721 @default.
• W2085753048 cites W2097972394 @default.
• W2085753048 cites W2103091768 @default.
• W2085753048 cites W2105624539 @default.
• W2085753048 cites W2115601182 @default.
• W2085753048 cites W2116421111 @default.
• W2085753048 cites W2116532213 @default.
• W2085753048 cites W2127020972 @default.
• W2085753048 cites W2139827960 @default.
• W2085753048 cites W2145283869 @default.
• W2085753048 cites W2145545196 @default.
• W2085753048 cites W2157852649 @default.
• W2085753048 cites W2160034406 @default.
• W2085753048 cites W2314085678 @default.
• W2085753048 cites W2325462033 @default.
• W2085753048 cites W4292542165 @default.
• W2085753048 doi "https://doi.org/10.1002/art.24817" @default.
• W2085753048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19790055" @default.
• W2085753048 hasPublicationYear "2009" @default.
• W2085753048 type Work @default.
• W2085753048 sameAs 2085753048 @default.
• W2085753048 citedByCount "109" @default.
• W2085753048 countsByYear W20857530482012 @default.
• W2085753048 countsByYear W20857530482013 @default.
• W2085753048 countsByYear W20857530482014 @default.
• W2085753048 countsByYear W20857530482015 @default.
• W2085753048 countsByYear W20857530482016 @default.
• W2085753048 countsByYear W20857530482017 @default.
• W2085753048 countsByYear W20857530482018 @default.
• W2085753048 countsByYear W20857530482019 @default.
• W2085753048 countsByYear W20857530482020 @default.
• W2085753048 countsByYear W20857530482021 @default.
• W2085753048 countsByYear W20857530482022 @default.
• W2085753048 countsByYear W20857530482023 @default.
• W2085753048 crossrefType "journal-article" @default.
• W2085753048 hasAuthorship W2085753048A5003547159 @default.
• W2085753048 hasAuthorship W2085753048A5004222660 @default.
• W2085753048 hasAuthorship W2085753048A5023006840 @default.
• W2085753048 hasAuthorship W2085753048A5035698889 @default.
• W2085753048 hasAuthorship W2085753048A5035905868 @default.
• W2085753048 hasAuthorship W2085753048A5046483439 @default.
• W2085753048 hasAuthorship W2085753048A5049958479 @default.
• W2085753048 hasAuthorship W2085753048A5057189629 @default.
• W2085753048 hasAuthorship W2085753048A5061107236 @default.
• W2085753048 hasAuthorship W2085753048A5067900184 @default.
• W2085753048 hasAuthorship W2085753048A5073066369 @default.
• W2085753048 hasAuthorship W2085753048A5077471575 @default.
• W2085753048 hasAuthorship W2085753048A5081286017 @default.
• W2085753048 hasBestOaLocation W20857530481 @default.
• W2085753048 hasConcept C105702510 @default.
• W2085753048 hasConcept C125473707 @default.
• W2085753048 hasConcept C126322002 @default.
• W2085753048 hasConcept C134018914 @default.
• W2085753048 hasConcept C142724271 @default.
• W2085753048 hasConcept C170493617 @default.
• W2085753048 hasConcept C185592680 @default.
• W2085753048 hasConcept C190283241 @default.
• W2085753048 hasConcept C196795494 @default.
• W2085753048 hasConcept C204232928 @default.
• W2085753048 hasConcept C204787440 @default.

• next